PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for
pancreatic cancer. Each treatment will be given for 3 months prior to surgery
Phase:
Phase 2
Details
Lead Sponsor:
Judith Dixon-Hughes
Collaborators:
NHS Greater Glasgow and Clyde University of Glasgow